MMP-11 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human MMP-11 (Stromelysin-3, UniProt P24347) expressed in HEK293 cells. Suited for enzymatic activity studies, inhibitor screening, and as a positive control for antibody validation against the full-length 488-aa sequence.
Expression system
HEK293
Cat. #
REC-MMP11

In stock

SKU
REC-MMP11
$498.00

Target Overview

MMP-11 (Matrix metalloproteinase-11, also known as Stromelysin-3) is a secreted zinc-dependent endopeptidase encoded by the MMP11 gene and catalogued under UniProt accession P24347. The mature protein spans 488 amino acids and localises to the extracellular space and extracellular matrix following signal-peptide cleavage and propeptide processing. Unlike several other MMP family members, MMP-11 is activated intracellularly by furin-type proprotein convertases prior to secretion, a property that distinguishes its activation mechanism and influences experimental design when studying its catalytic activity in vitro. This recombinant is produced in HEK293 cells, providing a mammalian glycosylation and folding environment that closely approximates the native protein. HEK293-derived material is particularly relevant for activity assays and inhibitor screens where post-translational processing affects substrate accessibility or inhibitor binding geometry. Researchers use this reagent in several contexts: (1) substrate cleavage assays to characterise MMP-11 catalytic activity against extracellular matrix and peptide substrates; (2) small-molecule inhibitor IC50 determinations, where a well-folded, active enzyme preparation is prerequisite for reliable potency measurements; (3) biophysical studies including surface plasmon resonance and isothermal titration calorimetry to characterise inhibitor or protein–protein interactions; and (4) antibody validation, where the recombinant serves as a defined positive control antigen in Western blot and dot-blot formats. Researchers pairing this recombinant with an anti-MMP-11 antibody can reference the matched Triple Point Biologics antibody reagent (SKU: RP-MMP11), which has been validated for Western blot against human MMP-11, with predicted cross-reactivity to mouse, rat, non-human primate, and dog.

Background

MMP-11 (Stromelysin-3) is a member of the matrix metalloproteinase family, a group of zinc-dependent proteases collectively responsible for the regulated degradation and remodelling of extracellular matrix components. MMP-11 was originally identified in breast carcinoma stromal fibroblasts and has since been studied as a research target across a range of epithelial malignancies, where its expression is predominantly localised to tumour-adjacent stromal cells rather than the cancer cells themselves. This stromal expression pattern has made MMP-11 a subject of sustained interest in tumour microenvironment research, particularly in studies examining how fibroblast-derived proteolytic activity modulates tumour progression. At the mechanistic level, MMP-11 has been investigated for its role in processing extracellular matrix substrates including laminin, fibronectin, and certain collagen species, though its substrate specificity relative to other MMPs remains an active area of characterisation. Its constitutive secretion in an already-active form — a consequence of intracellular furin-mediated processing — means that MMP-11 activity in tissue compartments is less tightly regulated at the activation step than is typical of classical MMPs, lending additional complexity to studies of its function. MMP-11 expression has been examined in published studies of esophageal, ovarian, and lung cancers, where broader MMP-driven stromal remodelling programmes have been characterised as contributors to tumour architecture and therapeutic response. Santos et al. (2026, PMID 41804162), for example, examined transcriptional regulation of metalloproteinases including MMP family members in lung cancer cell migration assays using 2D and 3D culture systems, illustrating the experimental context in which recombinant MMP proteins support mechanistic dissection. Beyond oncology, MMP-11 has been studied in the context of fibrotic remodelling and stromal biology, where extracellular matrix turnover intersects with inflammatory signalling. Researchers have used recombinant MMP proteins in these settings to define substrate hierarchies, establish kinetic parameters (Km, kcat), and profile the selectivity of broad-spectrum and selective MMP inhibitors — work that requires a defined, active enzyme preparation of known concentration. Triple Point Biologics has supplied proteinase and inhibitor antibody reagents since 1994. This recombinant MMP-11 is produced to support the same in vitro research workflows our antibody catalogue was built around.

Applications

  • Substrate cleavage activity assay using fluorogenic peptide substrates (e.g., Mca-RPKPVE-Nval-WRK(Dnp)-NH2 or gelatin zymography)
  • Small-molecule inhibitor IC50 determination in fluorescence-based enzymatic assays
  • Antibody validation positive control (Western blot and dot-blot) for anti-MMP-11 antibodies, including matched reagent RP-MMP11
  • Surface plasmon resonance (SPR) binding studies with candidate inhibitors or protein interaction partners
  • Kinetic parameter determination (Km, kcat, Ki) under defined buffer conditions
  • Recombinant antigen for ELISA standard curve generation or immunoassay calibration
  • Substrate specificity profiling by mass spectrometry-based degradomics
  • Tumour microenvironment in vitro modelling: stromal fibroblast co-culture systems requiring defined exogenous MMP-11 activity

References

  1. Yu Z et al. Targeting VEGF signaling and stromal remodeling enhances chemoimmunotherapy efficacy in esophageal cancer. J Immunother Cancer. 2026. doi:10.1136/jitc-2025-014249. PMID: 42173653.
  2. Chuang TD et al. In vivo inhibition of TDO2 in fibroids results in widespread alteration in the tumor transcriptome. Clin Sci (Lond). 2026. doi:10.1042/CS20260395. PMID: 42112999.
  3. Gutierrez A et al. The Role of MNX1-AS1 in Ovarian Cancer Resistance and Tumor Progression via RNA-RNA Interactions. Int J Mol Sci. 2026. doi:10.3390/ijms27083428. PMID: 42074071.
  4. Zhu H et al. Regulation of calcium homeostasis by S100A12 drives NETosis in chronic kidney disease. Inflamm Res. 2026. doi:10.1007/s00011-026-02215-8. PMID: 41862672.
  5. Santos AGPD et al. Modulatory Effects of Cirsimarin on Lung Cancer A549 Cells Migration in 2D and 3D Cultures Involves Transcriptional Regulation of Metalloproteinases. J Biochem Mol Toxicol. 2026. doi:10.1002/jbt.70772. PMID: 41804162.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; Extracellular matrix

Frequently Asked Questions

What molecular weight band should I expect for recombinant MMP-11 on SDS-PAGE or Western blot?

The mature, furin-processed form of MMP-11 runs at approximately 44–46 kDa under reducing SDS-PAGE conditions. Because this recombinant is produced in HEK293 cells with native-like glycosylation, the observed band may migrate slightly higher than the calculated molecular weight of the 488-amino-acid sequence (~54 kDa with propeptide) depending on glycan load. If you are seeing a band near 60 kDa, this likely reflects incomplete propeptide removal or glycosylation heterogeneity — both are expected in a subset of HEK293-expressed MMP-11 preparations.

Is recombinant MMP-11 supplied as the zymogen or the furin-activated mature form?

MMP-11 is unusual among MMPs in that it is activated intracellularly by furin-type proprotein convertases before secretion, rather than extracellularly like most family members. This recombinant is expressed in HEK293 cells, which endogenously express furin, so the material is supplied predominantly as the mature, active enzyme rather than as an intact zymogen. This distinction is critical: you do not need to include an exogenous activator (e.g., APMA) in your activity assay setup, and any comparison with other MMP zymogens requiring activation should account for this difference in starting form.

What substrates does MMP-11 cleave and which is best for an in vitro activity assay?

MMP-11 has a relatively restricted substrate repertoire compared to other stromelysins. It cleaves α1-protease inhibitor (α1-PI/SERPIN A1) and IGFBP-1, among other extracellular matrix components, but has limited activity against the classic MMP substrates gelatin or casein. For a fluorogenic activity assay, Mca-KPLGL-Dpa-AR-NH2 or the generic MMP FRET substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 can be used, though turnover is moderate. A starting concentration of 5–25 nM recombinant MMP-11 and 10–50 µM fluorogenic peptide substrate in assay buffer is a reasonable range for dose-response or inhibitor IC50 experiments.

What assay buffer should I use for MMP-11 activity assays and does it differ from standard MMP buffers?

The storage buffer for this recombinant is 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2. For activity assays, dilute into a working buffer of 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2, 0.05% Brij-35, omitting glycerol at concentrations above 2–5% to avoid fluorescence artifacts in FRET-based readouts. Zinc is already coordinated in the active site; supplemental ZnSO4 is not typically required but 1–10 µM is sometimes added for long incubations. Keep CaCl2 present throughout — calcium is essential for MMP-11 structural stability and loss of activity in its absence is rapid.

What starting concentration of recombinant MMP-11 is recommended for an IC50 inhibitor screening assay?

For inhibitor screening, use 5–20 nM recombinant MMP-11 with a fluorogenic peptide substrate at or near its Km (typically 10–30 µM for Mca-KPLGL-Dpa-AR-NH2). At this enzyme concentration, the assay is sensitive enough to detect low-nanomolar inhibitors without substrate depletion artifacts over a 60-minute read window. Include EDTA (10 mM) and 1,10-phenanthroline (1 mM) as positive inhibitor controls, and DMSO vehicle at ≤1% (v/v) to avoid activity loss. Pre-incubate enzyme with inhibitor for 30 minutes at 37°C before adding substrate to allow equilibrium binding.

Can I use recombinant MMP-11 as a positive control for Western blot with the RP-MMP11 rabbit polyclonal antibody?

Yes — this is one of the primary use cases for pairing REC-MMP11 with RP-MMP11. The antibody and recombinant are produced in the same lab and are guaranteed compatible for this application. Load 20–50 ng of recombinant MMP-11 per lane on a 10–12% SDS-PAGE gel under reducing conditions. Expect a clean band at ~44–46 kDa (mature form) with RP-MMP11 at a working dilution of 1:500–1:2000, depending on your secondary antibody system. This positive control is especially useful when working with low-expressing cell lysates or FFPE tissue where endogenous MMP-11 signal may be weak.

How much recombinant MMP-11 should I load for a Western blot positive control lane?

20–50 ng per lane is the recommended starting range when pairing with the matched RP-MMP11 antibody (SKU: RP-MMP11). At 20 ng, the band is typically detectable with an HRP-conjugated secondary and standard ECL in 1–5 minutes of exposure. If you are titrating antibody concentration or comparing signal to cell lysate lanes, run a 3-point series at 10, 25, and 50 ng. Avoid loading more than 100 ng — excess recombinant can bleed into adjacent lysate lanes and complicate quantification if you are running samples and controls on the same gel.

How should I store and handle recombinant MMP-11 to preserve activity after receipt?

Upon receipt, spin briefly to collect liquid, then aliquot into single-use volumes before freezing at -20°C. The storage buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2 — is formulated to maintain MMP-11 stability and metal coordination over multiple freeze-thaw cycles if avoided. Repeated freeze-thaw is the leading cause of activity loss for zinc-dependent proteinases; aliquots used intermittently should be stored at 4°C for no more than 7 days. Do not dilute to working concentrations in advance of the assay — prepare fresh dilutions in assay buffer on the day of use to minimize activity drift.

Validation imagery coming soon

Western blot validation figures for REC-MMP11 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →